Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Colorcon
Harvard Business School
Johnson and Johnson
Mallinckrodt

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,404,118

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,404,118
Title:Pichia ciferrii cells and use thereof
Abstract: The invention relates to genetically modified Pichia ciferrii cells, to the use thereof and to a method of producing sphingoid bases and sphingolipids.
Inventor(s): Kohler; Tim (Dorsten, DE), Schorsch; Christoph (Frankfurt am Main, DE), Boles; Eckhard (Darmstadt, DE), Andrea; Heiko (Marl, DE), Farwick; Mike (Essen, DE), Schaffer; Steffen (Herten, DE)
Assignee: EVONIK DEGUSSA GMBH (Essen, DE)
Application Number:14/238,248
Patent Claims:1. An genetically modified Pichia ciferrii cell, wherein said genetically modified Pichia ciferrii cell has, compared to its wild type, a reduced activity of an E.sub.1 enzyme encoded by the intron-free nucleic acid sequences selected from the group consisting of A) SEQ ID NO: 1, and B) a sequence which is at least 90% identical to SEQ ID NO: 1, wherein said activity of said E.sub.1 enzyme is the catalysis of the reaction 5,10-methylenetetrahydrofolate+L-glycine+H.sub.2O to tetrahydrofolate+L-serine.

2. The genetically modified Pichia ciferrii cell according to claim 1, wherein said reduction of enzymatic activity is achieved by modifying a gene comprising the nucleic acid sequence set forth in SEQ ID NO: 1, wherein the modification is selected from the group consisting of insertion of foreign DNA into the gene, deletion of at least a portion of the gene, point mutations in the gene sequence, exposing the gene to the influence of RNA interference, and replacement of a portion of the gene with foreign DNA.

3. The genetically modified Pichia ciferrii cell according to claim 2, wherein said foreign DNA is a selection marker gene that can be removed without leaving a trace and which leaves a deletion in the target gene.

4. The genetically modified Pichia ciferrii cell according to claim 1, wherein the Pichia ciferrii cell is obtained from strains selected from the group consisting of Pichia ciferrii NRRL Y-1031 F-60-10, and Pichia ciferrii CS.PC.DELTA.Pro2.

5. The genetically modified Pichia ciferrii cell according to claim 1, characterized in that the cell further has, compared to its wild type, an increased enzymatic activity of an enzyme E.sub.2, wherein said enzyme E.sub.2 catalyzes the reaction of sphinganine to phytosphingosine.

6. A method of producing an isolated Pichia ciferrii cell according to claim 1, said method comprising the steps of: I) providing an isolated Pichia ciferrii cell, and II) modifying at least one gene comprising any of the sequences selected from the nucleic acid sequence groups A) and B) specified in claim 1 by insertion of foreign DNA into the gene, deletion of at least parts of the gene, point mutations in the gene sequence, exposing the gene to the influence of RNA interference, and replacement of parts of the gene with foreign DNA.

7. A method of producing sphingoid bases and sphingolipids, said method comprising the steps of acting the cell according to claim 1 with a medium including a carbon source, b) culturing the cell under conditions which enable the cell to produce sphingoid bases and sphingolipids from said carbon source, and c) optionally isolating the sphingoid bases and sphingolipids produced.

8. The genetically modified Pichia ciferrii cell according to claim 2, wherein said replacement of a portion of the gene with foreign DNA is of the promoter region.

9. The genetically modified Pichia ciferrii cell according to claim 5, wherein said enzyme E.sub.2 is a sphinganine C4-hydroxylase.

10. The genetically modified Pichia ciferrii cell according to claim 9, wherein said sphinganine C4-hydroxylase is encoded by SEQ ID NO: 17.

11. The method according to claim 6, wherein said foreign DNA is DNA coding for a selection marker gene.

12. The method according to claim 6, wherein said replacement of parts of the gene with foreign DNA is of the promoter region.

13. The genetically modified Pichia ciferrii cell of claim 1, wherein said intron-free nucleic acid sequences consists of a sequence that is at least 95% identical to SEQ ID NO: 1.

14. The genetically modified Pichia ciferrii cell of claim 13, wherein said intron-free nucleic acid sequences consists of a sequence that is at least 99% identical to SEQ ID NO: 1.

Details for Patent 9,404,118

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2031-08-18
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2031-08-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Mallinckrodt
AstraZeneca
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.